Invasive Pneumococcal Disease in New Zealand, 2016

Since 17 October 2008, invasive pneumococcal disease (IPD) has been a notifiable disease in New Zealand. There were 480 cases of IPD notified in 2016, which equates to a rate of 10.2 cases per 100,000 population. This report presents information on cases of IPD that were notified in 2016, as well as trend data for recent years. Information relating to disease distribution in the population, risk factors, immunisation status, serotype distribution and antimicrobial susceptibility of S pneumoniae isolates is provided.

In June 2008, a 7-valent pneumococcal conjugate vaccine (PCV7), Prevenar® was added to the New Zealand childhood immunisation schedule. In July 2011, this was replaced with the 10-valent conjugate vaccine (PCV10), Synflorix® and in July 2014, Synflorix® was replaced by the 13-valent conjugate vaccine (PCV13), Prevenar13®. In July 2017, Synflorix® will be re-introduced to the childhood immunisation schedule and replace Prevenar13®. Synflorix® has cross-reactivity to serotype 19A, one of the three additional serotypes included in Prevenar13®.